Viatris (VTRS -1.45%) is a large and diverse pharmaceutical business that spun off from Pfizer in 2020. The company's medications are in 165 countries and much of its business centers around generic drugs. But while its operations are diverse, this isn't the type of enterprise that screams growth. Chances are, if you're considering Viatris for your portfolio, it's because of its dividend and low valuation. With a 3.9% yield, the healthcare stock offers investors a higher payout than the S&P 500 average of 1 ...